Brady boosts profit, revenue in 1H09; says ‘well placed’ for growth

Brady plc, specialists in trading, risk management and settlement software for metals and commodities, said sales increased 49% to £3.7m in the six to 30 June 2009.

Operating profit was up 706% to £0.27m compared to a low base of £0.03m for H1 2008. Pretax profit grew 42% to £0.31m.

Chairman Paul Fullagar said the growth in revenues and profits "demonstrates the continued success and momentum following the reorganisation in 2007 and execution of the new business plan set out in 2008.

"The sales organisation has been strengthened and a focus on our core business has generated improved operating margins, which has been further complemented by the addition of Comsoft. Comsoft was acquired and successfully integrated in the period, and continues to perform above its plan.

The Board said is confident Brady will meet its expectations for the full year and remains well placed for future growth."

CEO Gavin Lavelle said the Cambridge-based Group announced three significant new licence contracts in the first half of 2009.

In March Xstrata Copper selected Brady's Aquarius solution for its metal trading. This was the first sale of Aquarius since Brady acquired the specialist metals trading technology through its acquisition of Comsoft in January. Aquarius is also being put in place by Asarco.

In June Brady signed two further licence deals. The first was with a leading global investment bank and member of London Precious Metals Clearing Ltd who signed a contract to use Brady's technology for precious metals inventory management and connection to the Aurum clearing system. The second was with Japan's largest general trading company, who signed a contract to extend the use of Brady's trading and risk technology to include all of their global trading of both physical and derivative precious metals.

The Group anticipates there will be continuing pressure for its customers to address increasing regulatory and accounting compliance requirements, providing a strong market driver to improve internal trading and risk management, or to move away from internal legacy systems or spreadsheets.

About half of revenue is from Europe, 40% from North America and the remainder from Asia. The Group has continued to invest significantly in product development, most notably in functionality that supports a SMART interface for the LME, increasing trade automation, physical gold trading and enhanced value at risk capability.

In June, the Group said Robert Brady, currently Chief Technology Officer, will become a non-executive director at the end of September. Dr. Brady remains a major shareholder in the Company.

The Board said it is convinced Brady has built a strong foundation to support ongoing growth in the remainder of 2009 and beyond.

It continues to look for opportunities and is engaged with a number of potential candidates, in order to enhance its product offering and build on its customer base through selective further acquisitions.

Since May, the company's share price has grown by around a third. Brady is now valued at around £17.6m.

 



Previous articles
CSR’s 1Q08 revenues flat; short term prognosis disappoints market, share price sheds 20%
Solexa sees revenue stream for Genome Analyzer starting in 2Q
Generics Group boosted by public sector work; returns to the black, order book 'strong'
Alizyme goes into liquidation as litigation stumps funding talks
For the Record: Acambis lays out strategy for fighting all legal actions filed by Bavarian Nordic with regard to smallpox vaccine MVA.
CSR soars as Q1 beats market expectations; profits double, outlook strong
Market takes dim view of Brady’s 1H07; Board confident of prospects
BioProgress lives up to its name as it goes forward in 2006
CamSemi raises £13m in ‘C Round’ funding; first products shipping in volume
Cyan wins strong orders in 1Q09; prospects for 2H09 ‘exciting’
Subscribe

 

Managed Hosting by NTT Managed Hosting
SEO London by IdeaTaxi.com
Corporate profiles

 • Psynova


Dr Sabine Bahn MD, PhD, MRCPsych
Founder


Psynova Ltd is a new company, established in 2005 by Dr Sabine Bahn MD, PhD, MRCPsych, and Prof Chris Lowe PhD of the University of Cambridge, for the commercial development and exploitation of novel biomarkers for neuropsychiatric disorders. Building on 12 years of research by Dr Bahn, Psynova has

[Psynova's profile]


Top20 Index




Currently: 129.81

Best Mortgage Rate
Connect to the loans specialists to choose the best mortgage rate you can afford.

Marcus Evans
The Marcus Evans group offers a huge range of business products, events and courses.

Marcus Evans scam events
Don't suffer from fraud - join one of the Marcus Evans scam events today.

IFL
IFL are leaders in the Chrome industry. To find out more visit www.ifml.com